Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Name
e000878.full.pdf
Description
Published version
Size
406.56 KB
Format
Adobe PDF
Checksum (MD5)
bf358a755d031f28707cec5792e987b3
Author(s)
Spranger, Stefani
Date Issued
January 2020
Journal
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Citation
Ascierto, Paolo Antonio, et al., "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." Journal for ImmunoTherapy of Cancer 8, 1 (Jan. 2020): no. e000878 doi 10.1136/jitc-2020-000878 ©2020 Author(s)
Version
Final published version
Abstract
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. ©2020
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution NonCommercial License 4.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1136/jitc-2020-000878
